Alisertib
Alisertib is a pharmaceutical drug with 53 clinical trials. Currently 5 active trials ongoing. Historical success rate of 90.9%.
Success Metrics
Based on 40 completed trials
Phase Distribution
Phase Distribution
31
Early Stage
20
Mid Stage
1
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
88.9%
40 of 45 finished
11.1%
5 ended early
5
trials recruiting
53
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
Targeting Aurora A Kinase to Overcome Treatment Resistance in Advanced HR+/HER2+ Breast Cancer
Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma
A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer
Clinical Trials (53)
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
Targeting Aurora A Kinase to Overcome Treatment Resistance in Advanced HR+/HER2+ Breast Cancer
Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma
A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer
Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors
A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)
Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer
Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer
Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer
Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas
Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma
Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer
Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer
MLN8237 for Treatment of Participants With Ovarian, Fallopian Tube, or Peritoneal Carcinoma
Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 53